Heart and Vascular Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the University of Kiel, Bad Segeberg, Germany.
Am J Cardiol. 2010 Apr 1;105(7):967-71. doi: 10.1016/j.amjcard.2009.11.021. Epub 2010 Feb 13.
Primary percutaneous coronary intervention (PCI) and intra-aortic balloon pump counterpulsation (IABP) are established treatment modalities in acute myocardial infarction complicated by cardiogenic shock. We hypothesized that the insertion of the IABP before primary PCI might result in better survival of patients with cardiogenic shock compared to postponing the insertion to after primary PCI. We, therefore, retrospectively studied 48 patients who had undergone primary PCI with IABP because of cardiogenic shock complicating acute myocardial infarction (26 patients received the IABP before and 22 patients after primary PCI). No significant differences were present in the baseline clinical characteristics between the 2 groups. The mean number of diseased vessels was greater in the group of patients treated with the IABP before primary PCI (2.8 +/- 0.5 vs 2.3 +/- 0.7, p = 0.012), but the difference in the number of treated vessels was not significant. The peak creatine kinase and creatine kinase -MB levels were lower in patients treated with the IABP before primary PCI (median 1,077, interquartile range 438 to 2067 vs median 3,299, interquartile range 695 to 6,834, p = 0.047, and median 95, interquartile range 34 to 196 vs median 192, interquartile range 82 to 467, p = 0.048, respectively). In-hospital mortality and the overall incidence of major adverse cardiac and cerebrovascular events were significantly lower in the group of patients receiving the IABP before primary PCI (19% vs 59% and 23% vs 77%, p = 0.007 and p = 0.0004, respectively). Multivariate analysis identified renal failure (odds ratio 15.2, 95% confidence interval 3.13 to 73.66) and insertion of the IABP after PCI (odds ratio 5.2, 95% confidence interval 1.09 to 24.76) as the only independent predictors of in-hospital mortality. In conclusion, the results of the present study suggest that patients with cardiogenic shock complicating acute myocardial infarction who undergo primary PCI assisted by IABP have a more favorable in-hospital outcome and lower in-hospital mortality than patients who receive IABP after PCI.
在急性心肌梗死并发心源性休克的情况下,经皮冠状动脉介入治疗(PCI)和主动脉内球囊反搏(IABP)是既定的治疗方法。我们假设在进行 PCI 之前插入 IABP 可能会导致心源性休克患者的生存率优于在 PCI 后插入 IABP。因此,我们回顾性地研究了 48 例因急性心肌梗死并发心源性休克而行 PCI 并置入 IABP 的患者(26 例在 PCI 前,22 例在 PCI 后)。两组患者的基线临床特征无显著差异。在接受 PCI 前接受 IABP 治疗的患者中,病变血管的平均数量较大(2.8 ± 0.5 与 2.3 ± 0.7,p = 0.012),但治疗血管的数量差异无统计学意义。在接受 PCI 前接受 IABP 治疗的患者中,肌酸激酶和肌酸激酶-MB 的峰值水平较低(中位数 1077,四分位距 438 至 2067 与中位数 3299,四分位距 695 至 6834,p = 0.047,中位数 95,四分位距 34 至 196 与中位数 192,四分位距 82 至 467,p = 0.048)。在住院期间死亡率和主要心脏和脑血管不良事件的总发生率在接受 PCI 前接受 IABP 治疗的患者中显著较低(19%与 59%和 23%与 77%,p = 0.007 和 p = 0.0004)。多变量分析确定肾功能衰竭(优势比 15.2,95%置信区间 3.13 至 73.66)和 PCI 后插入 IABP(优势比 5.2,95%置信区间 1.09 至 24.76)是住院期间死亡率的唯一独立预测因素。总之,本研究的结果表明,在急性心肌梗死并发心源性休克的患者中,接受 IABP 辅助的 PCI 治疗的患者比接受 PCI 后接受 IABP 的患者具有更好的住院预后和更低的住院死亡率。